In August 2017 the Government changed the funding system for pre-registration undergraduate nurse training. The intention of the reforms is to boost participation and secure the future supply of home-grown nurses to the National Health Service and enable universities to create additional nursing and midwifery training places.<\/p>
<\/p>
On 7 February, the University and College Admissions Service (UCAS) published full-time undergraduate nursing and midwifery applications made by the 15 January deadline. This data showed a 4.5% increase in the number of applicants compared to the same point in 2018.<\/p>
<\/p>
Based on the data UCAS published in February, there is no intention to provide bursaries for nurse training course fees.<\/p>
<\/p>
On 9 May 2018 the former Secretary of State for Health (Rt. hon. Jeremy Hunt MP) announced a £10,000 package of golden hello payments for 2018/19 loan funded postgraduate nursing students that take up employment in learning disability, mental health or community service nursing roles. The full details of this incentive will be published in due course.<\/p>
<\/p>
The NHS Long Term Plan, published on 7 January 2019, sets out a vital strategic framework to ensure that over the next 10 years the NHS will have the staff it needs so that nurses have the time they need to care, working in a supportive culture that allows them to provide the expert compassionate care they are committed to providing.<\/p>
<\/p>
My Rt. hon. Friend the Secretary of State for Health and Social Care has commissioned Baroness Dido Harding, working closely with Sir David Behan, to lead a number of programmes to engage with key NHS interests to develop a detailed workforce implementation plan. These programmes will consider detailed proposals to grow the workforce, including consideration of additional staff and skills required, build a supportive working culture in the NHS and ensure first rate leadership for NHS staff.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-02-18", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "220204"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-18T12:22:18.743Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nurses: Training"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of nurse training course fees and bursaries being paid for by the NHS subject to the completion of several years of post-registration work as a nurse.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"} } , "tablingMemberConstituency" : {"_value" : "York Outer"} , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"} ], "uin" : "220203"} , {"_about" : "http://data.parliament.uk/resources/1058964", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058964/answer", "answerText" : {"_value" : "
Our number one priority is to ensure patients continue to have unhindered access to medicines as we exit the European Union and we are working with all sectors in the supply chain to ensure this happens.<\/p>
<\/p>
We understand that medicines for rheumatoid arthritis are vitally important to many people in this country. Our \u2018no deal\u2019 medicines supply contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the EU/European Economic Area (EEA) to ensure that the supply of essential medicines, including medicines for patients with rheumatoid arthritis, is not disrupted.<\/p>
<\/p>
In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines, including those for rheumatoid arthritis, to the UK that come from, or via, the EU/EEA asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019.<\/p>
<\/p>
On 7 December, the Government published updated reasonable worst-case scenario border disruption planning assumptions in the event of a \u2018no deal\u2019 EU exit. Medicines and medical products are prioritised in cross-Government planning, and the Department is working with relevant partners across Government and industry to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely into the UK.<\/p>
<\/p>
Throughout enacting our plans, we have received very good engagement from industry, including on their plans to stockpile medicines. They share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a \u2018no deal\u2019 EU exit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "219497"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:06:21.49Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Arthritis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the supply of medications for rheumatoid arthritis in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4463", "label" : {"_value" : "Biography information for Chris Stephens"} } , "tablingMemberConstituency" : {"_value" : "Glasgow South West"} , "tablingMemberPrinted" : [{"_value" : "Chris Stephens"} ], "uin" : "219496"} , {"_about" : "http://data.parliament.uk/resources/1058976", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058976/answer", "answerText" : {"_value" : "
Our number one priority is to ensure patients continue to have unhindered access to medicines as we exit the European Union and we are working with all sectors in the supply chain to ensure this happens.<\/p>
<\/p>
We understand that medicines for rheumatoid arthritis are vitally important to many people in this country. Our \u2018no deal\u2019 medicines supply contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the EU/European Economic Area (EEA) to ensure that the supply of essential medicines, including medicines for patients with rheumatoid arthritis, is not disrupted.<\/p>
<\/p>
In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines, including those for rheumatoid arthritis, to the UK that come from, or via, the EU/EEA asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019.<\/p>
<\/p>
On 7 December, the Government published updated reasonable worst-case scenario border disruption planning assumptions in the event of a \u2018no deal\u2019 EU exit. Medicines and medical products are prioritised in cross-Government planning, and the Department is working with relevant partners across Government and industry to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely into the UK.<\/p>
<\/p>
Throughout enacting our plans, we have received very good engagement from industry, including on their plans to stockpile medicines. They share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a \u2018no deal\u2019 EU exit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "219496"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:06:21.567Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) protect patients and (b) ensure pharmaceutical companies have a minimum of six weeks\u2019 additional supply of vital medications over and above existing business-as-usual buffer stocks in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4463", "label" : {"_value" : "Biography information for Chris Stephens"} } , "tablingMemberConstituency" : {"_value" : "Glasgow South West"} , "tablingMemberPrinted" : [{"_value" : "Chris Stephens"} ], "uin" : "219497"} , {"_about" : "http://data.parliament.uk/resources/1059045", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1059045/answer", "answerText" : {"_value" : "
Information is not available in the format requested. National and individual ambulance National Health Service trust level performance is available and is published monthly by NHS England. This can be found online at the following link:<\/p>
<\/p>